HighMark Wealth Management’s Royalty Pharma RPRX Stock Holding History

HighMark Wealth Management’s Portfolio RPRX Stock Details RPRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-82	Closed	-$2.52K	–	580
2023 Q2	$2.52K	Buy	82 +21	+34%	+$711	﹤0.01%	436
2023 Q1	$2.2K	Buy	+61	New	+$2.26K	﹤0.01%	491
2022 Q4	–	Sell	-64	Closed	-$3K	–	560
2022 Q3	$3K	Hold	64	–	–	﹤0.01%	400
2022 Q2	$3K	Hold	64	–	–	﹤0.01%	406
2022 Q1	$2K	Hold	64	–	–	﹤0.01%	454
2021 Q4	$3K	Hold	64	–	–	﹤0.01%	414
2021 Q3	$2K	Sell	64 -8	-11%	-$311	﹤0.01%	461
2021 Q2	$3K	Sell	72 -18	-20%	-$766	﹤0.01%	428
2021 Q1	$4K	Buy	90 +23	+34%	+$1.09K	﹤0.01%	370
2020 Q4	$3K	Buy	67 +7	+12%	+$297	﹤0.01%	391
2020 Q3	$3K	Buy	+60	New	+$2.57K	﹤0.01%	376

Other funds holding RPRX

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

HighMark Wealth Management's RPRX Position: Q3 2023 in Review

HighMark Wealth Management sold out of Royalty Pharma (RPRX) in Q3 2023, closing a stake of 82 shares — an estimated $2.52K sold.

HighMark Wealth Management first reported a position in RPRX in Q3 2020 and held it in 11 quarters. The position peaked at $4K in Q1 2021. 313 funds tracked by Wall St. Rank hold RPRX as of Q3 2023.

HighMark Wealth Management reported no remaining Royalty Pharma position as of Q3 2023 after selling out during the quarter.
HighMark Wealth Management sold 82 Royalty Pharma shares in Q3 2023, an estimated $2.52K.
HighMark Wealth Management first reported a position in Royalty Pharma in Q3 2020 and held it in 11 quarters.
HighMark Wealth Management's Royalty Pharma position peaked at $4K in Q1 2021.
313 funds tracked by Wall St. Rank held Royalty Pharma as of Q3 2023.

Based on HighMark Wealth Management's 13F filing for Q3 2023, filed 18 Oct 2023.